CathWorks
About CathWorks
CathWorks develops and markets the FFRangio system, a drug-free, wire-free physiologic assessment tool for the entire coronary tree. The technology combines artificial intelligence and advanced computational science to derive physiologic information from routine angiograms, enabling quick, intraprocedural evaluation of coronary function without stimulation or invasive pressure wires. The company serves interventional cardiology across multiple geographies, providing real-time hemodynamic insights to support clinical decision making in coronary interventions.
Recent News
SCAI Expert Opinion Highlights Advances in Wire-Free Angiography-Derived Physiology for Coronary Assessment
Q&A: Duke’s Amanda Randles, Ph.D., on the Future of Digital Twin Innovation
Noninvasive FFR Measures Match Wire-Based Assessment: ALL RISE and FAST III
Medtronic Advances Its Innovation Strategy with Intent to Acquire CathWorks
